By Dean Seal


Takeda Pharmaceutical said the U.S. Food and Drug Administration has approved subcutaneous administration of Entyvio as a maintenance therapy for adults with Crohn's disease.

The company said Thursday that the regulatory approval is specifically for subcutaneous administration in adults with moderately to severely active Crohn's after induction therapy with intravenous Entyvio.

Subcutaneous administration of the treatment was approved in September for maintenance therapy of adults with moderately to severely active ulcerative colitis.

The treatment is available in the U.S. as a single-dose prefilled pen, known as the Entyvio Pen.


Write to Dean Seal at dean.seal@wsj.com


(END) Dow Jones Newswires

04-18-24 1934ET